{
    "Trade/Device Name(s)": [
        "ARK Fentanyl Assay",
        "ARK\u2122 Fentanyl Assay"
    ],
    "Submitter Information": "ARK Diagnostics, Inc.",
    "510(k) Number": "K180427",
    "Predicate Device Reference 510(k) Number(s)": [
        "K161216"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "June 6, 2018",
    "Summary Letter Received Date": "May 4, 2018",
    "Submission Date": "May 3, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Fentanyl"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzer",
        "Beckman Coulter AU680"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay (EIA)",
        "Spectrophotometry"
    ],
    "Methodologies": [
        "Enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for ARK Fentanyl Assay, a homogeneous enzyme immunoassay for qualitative detection of fentanyl in urine using automated clinical chemistry analyzers",
    "Indications for Use Summary": "Qualitative detection of fentanyl in human urine at a cutoff concentration of 1.0 ng/mL; intended for use in laboratories with automated clinical chemistry analyzers as a preliminary analytical test, with confirmation by GC/MS or LC-MS/MS.",
    "fda_folder": "Toxicology"
}